

**Juxtapid® (Iomitapide)**  
Effective 11/26/18

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	This medication has been designated as a limited distribution specialty product and must be filled at a contracted specialty pharmacy; dispensing is available through Dohmen Life Science Services.		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Juxtapid is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

### Coverage Guidelines

- Member has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
- Member is ≥ 18 years of age AND
- Member is new to AllWays Health Partners and has already been started and stabilized on Juxtapid®
- OR**
- Member has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
- Member is ≥ 18 years of age AND
- Member is adherent to a low-fat diet (< 20% of energy supplied by dietary fat intake) and will be taking a dietary supplement to prevent nutritional deficiencies AND
- Member has had a documented side-effect, allergy, inadequate response, treatment failure, or contraindication to treatment with a high potency HMG Co-A reductase inhibitor (e.g. statin), including atorvastatin or rosuvastatin used in combination with ezetimibe, a fibric acid derivative, and/or cholestyramine AND
- Member has had an inadequate response, treatment failure, or has a contraindication to lipid apheresis therapy AND
- Member has had an inadequate response, treatment failure, or has a contraindication to Kynamro®\*AND



- Member has had an inadequate response, treatment failure, or has a contraindication with a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor (i.e. Praluent or Repatha)
- If female, member has had a negative pregnancy test prior to initiation of treatment with Juxtapid®

\* Note: Needle phobia is not considered an adequate justification for not utilizing Kynamro®

### Limitations

1. A quantity limit of 28 capsules per 28 days applies.

### References

1. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al; Writing Committee. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2016;68(1):92-125.[PubMed 27046161]Farnier M, Bruckert E. Severe familial hypercholesterolemia:
2. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult T treatment Panel III Guidelines. *Circulation*. 2004; 110:227-39.
3. Juxtapid (Iomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc; August 2017.
4. Kynamro (mipomersen) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2016.
5. National Cholesterol Education Program (NCEP). Detection, evaluation, and treatment of high blood cholesterol in adults (adult t treatment panel III) final report, 2002 [guideline on the internet]. NCEP. 2002. Available at: <http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm>. Accessed December 28, 2012.
6. National Heart Lung and Blood Institute. Clinical Practice Guidelines and Reports under Development. Available at:
7. <http://www.nhlbi.nih.gov/guidelines/indevelop.htm> . Accessed December 28, 2012.
8. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract*. 2017;23(suppl 2):1-87.[PubMed 28437620]10.4158/EP171764.APPGL.

### Review History

06/01/18 – Implemented

2/26/18 – Reviewed

11/26/18 – Reviewed

### Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.